nach oben

Erschienen in:

13.03.2020 | Original Article

Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes

verfasst von: Asmaa M. Zahran, Helal F. Hetta, Amal Rayan, Abeer Sharaf Eldin, Elham Ahmed Hassan, Hussein Fakhry, Ahmed Soliman, Omnia El-Badawy

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Activation of the immune checkpoints and expression of chemokines and chemokine receptors have been reported to promote HCC progression. This study aimed to assess the differential expression of Tim-3, PD-1, and CCR5 on peripheral blood lymphocytes from patients with HCV-related HCC and correlate their expression with the treatment outcomes.

Patients and methods

The study incorporated 40 patients with chronic HCV-related HCC and 40 healthy controls. Patients were radiologically assessed for hepatic focal lesions and portal vein thrombosis. Response to HCC treatment and overall survival (OS) outcomes were determined. The expression of Tim-3, PD-1, and CCR5 among CD19⁺, CD4⁺, and CD8⁺ lymphocytes was assessed by flow cytometry.

Results

Higher frequencies of CD4⁺ and CD8⁺ cells expressing each of Tim-3 and PD-1 and PD-1⁺CD19⁺ cells were observed in the HCV-related HCC patients in comparison with controls. The highest expression of Tim-3 and PD-1 was by the CD8⁺ cells. Strong relations were detected among PD-1⁺CD19⁺, PD-1⁺CD4⁺ and PD-1⁺CD8⁺ cells. Elevated levels of PD-1⁺ lymphocytes were significantly associated with poor treatment response and shorter OS.

Conclusion

Modulation of the expression of immune checkpoints as Tim-3 and PD-1, and of CCR5 on T cells is somehow related to HCC. CD8⁺ T cells expressing PD-1 were the most relevant to HCC prognosis (OS and treatment response) and could represent a promising target for immune therapy against HCC. Future studies need to focus on exploring PD-1⁺ B cells and Tim-3⁺CD4⁺ cells, which seem to play a significant role in the pathogenesis of HCC.

Nur mit Berechtigung zugänglich

Rayan A, Zahran A, El-Badawy O, Soliman A (2019) P-056 Differential expression of CCR5, TIM3 and PD-1 on peripheral blood T and B lymphocytes from hepatitis C patients with hepatocellular carcinoma and their impact on treatment outcomes. Ann Oncol 30((Supplement_4)):mdz155.055

Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42(Suppl 3):S206–214. https://doi.org/10.1016/s1590-8658(10)60507-5 CrossRefPubMedPubMedCentral

Laursen L (2014) A preventable cancer. Nature 516(7529):S2–3. https://doi.org/10.1038/516S2a CrossRefPubMed

Zahran AM, Abdel-Rahim MH, Refaat A, Sayed M, Othman MM, Khalak LMR, Hetta HF (2020) Circulating hematopoietic stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: contribution to diagnosis and prognosis. Acta Oncol 59(1):33–39CrossRefPubMed

Chaturvedi VK, Singh A, Dubey SK, Hetta HF, John J, Singh M (2019) Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microb Pathog 128:184–194CrossRefPubMed

Anzola M (2004) Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepatitis 11(5):383–393. https://doi.org/10.1111/j.1365-2893.2004.00521.x CrossRef

Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, Medhat A, Nassar MI, Sherman KE (2016) Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis. J Med Microbiol 65(8):703CrossRefPubMedPubMedCentral

Zahran AM, Nafady-Hego H, Mansor SG, Abbas WA, Abdel-Malek MO, Mekky MA, Hetta HF (2019) Increased frequency and FOXP3 expression of human CD8+ CD25High+ T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma. Hum Immunol 80:510–516CrossRefPubMed

Hassan EA, Ahmed EH, Nafee AM, El-Gafary N, Hetta HF, El-Mokhtar MA (2019) Regulatory T cells, IL10 and IL6 in HCV related hepatocellular carcinoma after transarterial chemoembolization (TACE). Egypt J Immunol 26:69–78PubMed

10.

Zahran AM, Ashmawy AM, Rayan A, Elkady A, Elsherbiny NM, Hetta HF (2018) Frequency and implications of natural killer and natural killer T cells in hepatocellular carcinoma. Egypt J Immunol 25:45PubMed

11.

Elsegood CL, Tirnitz-Parker JE, Olynyk JK, Yeoh GC (2017) Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clin Transl Immunol 6(11):e161. https://doi.org/10.1038/cti.2017.47 CrossRef

12.

Sarvaria A, Madrigal JA, Saudemont A (2017) B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 14(8):662CrossRefPubMedPubMedCentral

13.

Hetta H, Elkady A, Tohamy T, Badary M (2016) Regulatory B cells: key players in hepatocellular carcinoma progression. Gastroenterol Hepatol Open Access 5(2):00136CrossRef

14.

Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C (2013) B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2(7):e25443. https://doi.org/10.4161/onci.25443 CrossRefPubMedPubMedCentral

15.

Inoue S, Leitner WW, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Can Res 66(15):7741–7747. https://doi.org/10.1158/0008-5472.can-05-3766 CrossRef

16.

Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA 108(26):10662–10667. https://doi.org/10.1073/pnas.1100994108 CrossRefPubMedPubMedCentral

17.

DiLillo DJ, Yanaba K, Tedder TF (2010) B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (Baltimore, Md : 1950) 184(7):4006–4016. https://doi.org/10.4049/jimmunol.0903009 CrossRef

18.

Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE (2009) In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol (Baltimore, Md : 1950) 183(5):3195–3203. https://doi.org/10.4049/jimmunol.0803773 CrossRef

19.

Raufi A, Tirona MT (2017) Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. Cancer Manag Res 9:19–27. https://doi.org/10.2147/cmar.s111673 CrossRefPubMedPubMedCentral

20.

Hetta HF, Zahran AM, Mansor SG, Abdel-Malek MO, Mekky MA, Abbas WA (2019) Frequency and implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. J Med Virol 91(7):1319–1328CrossRefPubMed

21.

Zahran AM, Zahran ZAM, El-Badawy O, Abdel-Rahim MH, Ali WA, Rayan A, El-Masry MA, Abozaid MA, Hetta HF (2019) Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. Immunol Res 67(2–3):157–165. https://doi.org/10.1007/s12026-019-09075-x CrossRefPubMed

22.

Hetta HF, Khairy H, Ismail S (2017) Circulating IL17A and IFN-gamma serum levels in cirrhotic hepatitis C virus infected patients with autoimmune thyroiditis. Int J Curr Microbiol Appl Sci 6(3):1972–1983CrossRef

23.

Liang CM, Chen L, Hu H, Ma HY, Gao LL, Qin J, Zhong CP (2015) Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol 7(10):1390–1402. https://doi.org/10.4254/wjh.v7.i10.1390 CrossRefPubMedPubMedCentral

24.

Nahon P, Sutton A, Rufat P, Simon C, Trinchet JC, Gattegno L, Beaugrand M, Charnaux N (2008) Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 14(5):713–719CrossRefPubMedPubMedCentral

25.

Das M, Zhu C, Kuchroo VK (2017) Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 276(1):97–111. https://doi.org/10.1111/imr.12520 CrossRefPubMedPubMedCentral

26.

Hato T, Goyal L, Greten TF, Duda DG, Zhu AX (2014) Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (Baltimore, MD) 60(5):1776–1782. https://doi.org/10.1002/hep.27246 CrossRef

27.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331 CrossRefPubMed

28.

Chen J, Jiang CC, Jin L, Zhang XD (2016) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27(3):409–416. https://doi.org/10.1093/annonc/mdv615 CrossRefPubMed

29.

Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM (2002) PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32(3):634–643. https://doi.org/10.1002/1521-4141(200203)32:3%3c634:aid-immu634%3e3.0.co;2-9 CrossRefPubMed

30.

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027–1034. https://doi.org/10.1084/jem.192.7.1027 CrossRefPubMedPubMedCentral

31.

Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54(4):307–314. https://doi.org/10.1007/s00262-004-0593-x CrossRefPubMed

32.

Liu Y (2018) Immunomodulatory effects of Tim-3 and PD-1 on chronic hepatitis B virus infection. Infect Int 7(1):6–11CrossRef

33.

Missale G, Cariani E (2018) Time for hepatocellular carcinoma immunotherapy: insights for successful clinical applications in this challenging tumor. Hepatoma Res 4:22. https://doi.org/10.20517/2394-5079.2018.72 CrossRef

34.

Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, Castelblanco N, Kuchroo V, Gretch DR, Rosen HR (2009) Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 83(18):9122–9130CrossRefPubMedPubMedCentral

35.

Wu W, Shi Y, Li J, Chen F, Chen Z, Zheng M (2011) Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. Virol J 8(1):113CrossRefPubMedPubMedCentral

36.

Schmidt J, Blum HE, Thimme R (2013) T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect 2(3):e15. https://doi.org/10.1038/emi.2013.14 CrossRefPubMedPubMedCentral

37.

Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, Zou W (2012) Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology (Baltimore, MD) 56(4):1342–1351. https://doi.org/10.1002/hep.25777 CrossRef

38.

Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128(4):887–896. https://doi.org/10.1002/ijc.25397 CrossRefPubMed

39.

He G, Zhang H, Zhou J, Wang B, Chen Y, Kong Y, Xie X, Wang X, Fei R, Wei L (2015) Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 34(1):141CrossRefPubMedPubMedCentral

40.

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649CrossRefPubMed

41.

Tsou P, Katayama H, Ostrin EJ, Hanash SM (2016) The emerging role of B cells in tumor immunity. Can Res 76(19):5597–5601. https://doi.org/10.1158/0008-5472.can-16-0431 CrossRef

42.

Nelson BH (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185(9):4977–4982CrossRefPubMed

43.

Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ, Chen DP, Zhao XY, Zhao Q, Li XF, Liu CL, Zheng L, Kuang DM (2016) PD-1hi Identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov 6(5):546–559. https://doi.org/10.1158/2159-8290.cd-15-1408 CrossRefPubMed

44.

Fukada K, Sobao Y, Tomiyama H, Oka S, Takiguchi M (2002) Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J Immunol 168(5):2225–2232CrossRefPubMed

45.

Luther SA, Cyster JG (2001) Chemokines as regulators of T cell differentiation. Nat Immunol 2(2):102CrossRefPubMed

46.

Butrym A, Kryczek I, Dlubek D, Jaskula E, Lange A, Jurczyszyn A, Mazur G (2018) High expression of CC chemokine receptor 5 (CCR5) promotes disease progression in patients with B-cell non-Hodgkin lymphomas. Curr Probl Cancer 42(2):268–275CrossRefPubMed

47.

Liu Y, Poon RT, Feng X, Yu WC, Luk JM, Fan ST (2004) Reduced expression of chemokine receptors on peripheral blood lymphocytes in patients with hepatocellular carcinoma. Am J Gastroenterol 99(6):1111–1121. https://doi.org/10.1111/j.1572-0241.2004.30265.x CrossRefPubMed

48.

Liu Y, Poon RT, Hughes J, Feng X, Yu WC, Fan ST (2005) Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma. Clin Immunol 114(2):174–182CrossRefPubMed

49.

Gonzalez-Martin A, Mira E, Manes S (2012) CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells. Oncoimmunology 1(1):106–108. https://doi.org/10.4161/onci.1.1.17995 CrossRefPubMedPubMedCentral

50.

Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16(2):161–168. https://doi.org/10.1016/S1473-3099(15)00424-7 CrossRefPubMed

51.

Ren Z, Peng H, Fu Y-X (2016) PD-1 shapes B cells as evildoers in the tumor microenvironment. Cancer Discov 6(5):477–478CrossRefPubMedPubMedCentral

52.

Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC (2013) TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2(4):e23849. https://doi.org/10.4161/onci.23849 CrossRefPubMedPubMedCentral

53.

World Health Organization (2017) Global hepatitis report 2017. World Health Organization, Washington

54.

Mekky MA, Abdel-Malek MO, Osman HA, Abdel-Aziz EM, Hashim A-KA, Hetta HF, Morsy KH (2019) Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease. Clin Res Hepatol Gastroenterol 43(1):82–87CrossRefPubMed

55.

Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA, Osman HA, Morsy KH, Hetta HF (2019) Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study. Infect Drug Resist 12:273CrossRefPubMedPubMedCentral

56.

Mazouz S, Boisvert M, Shoukry NH, Lamarre D (2018) Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C. Can Liver J 1(2):78–105CrossRef

57.

Abdel-Hameed EA, Rouster SD, Ji H, Ulm A, Hetta HF, Anwar N, Sherman KE, Shata MTM (2016) Evaluating the role of cellular immune responses in the emergence of HCV NS3 resistance mutations during protease inhibitor therapy. Viral Immunol 29(4):252–258CrossRefPubMedPubMedCentral

58.

Zhang Y, Cai P, Liang T, Wang L, Hu L (2017) TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis. Oncotarget 8(19):31705CrossRefPubMedPubMedCentral

59.

Zahran AM, Saleh M, Mostafa F, Sayed MM, Rayan A, Ali AM, Hetta HF (2018) Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. Cancer Biomarkers 22(3):587–595CrossRefPubMed

60.

Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M (2016) NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531(7593):253CrossRefPubMedPubMedCentral

Titel: Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes
verfasst von: Asmaa M. Zahran
Helal F. Hetta
Amal Rayan
Abeer Sharaf Eldin
Elham Ahmed Hassan
Hussein Fakhry
Ahmed Soliman
Omnia El-Badawy
Publikationsdatum: 13.03.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 7/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02465-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes

Abstract

Background and objective

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background and objective

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target

Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis

Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets

Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie